MABp1

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Evangelos J. Giamarellos-Bourboulis, M.D.

Conditions

Advanced CancersHealthyHidradenitis Suppurativa

Phase 1

A First in Man Study of MABp1 in Patients With Advanced Cancers

CompletedNCT01021072

Janssen Research & Development, LLCAdvanced Cancers

Start: 2010-03-31End: 2013-08-31Updated: 2021-02-16

A Pharmacokinetic Study of MABp1 in Healthy Volunteers

CompletedNCT03047317

Janssen Research & Development, LLCHealthy

Start: 2017-02-15End: 2017-03-31Updated: 2021-02-16

Phase 2

MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB

CompletedNCT02643654

Evangelos J. Giamarellos-Bourboulis, M.D.Hidradenitis Suppurativa

Start: 2015-12-31End: 2017-02-28Updated: 2017-03-01

Related Papers

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

2014-04-17153 citations